Real world utilization of REGEN-COV2 at a community hospital
| Autor: | Jordan Ash, Sarah Schritter, Anthony Santarelli, John Ashurst, James A. Wells, Tyson Dietrich, Rachael Leavitt |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Monoclonal antibody
Male medicine.medical_specialty Emergency Use Authorization Coronavirus disease 2019 (COVID-19) Patient demographics Casirivimab Hospitals Community Antibodies Monoclonal Humanized Antiviral Agents Article Cohort Studies medicine Outpatient setting Ambulatory Care Humans Aged Adult patients business.industry Age Factors COVID-19 General Medicine Emergency department Middle Aged REGN-COV2 Antibodies Neutralizing Community hospital COVID-19 Drug Treatment Hospitalization Drug Combinations Emergency medicine Emergency Medicine Female business Emergency Service Hospital Viral load Imdevimab |
| Zdroj: | The American Journal of Emergency Medicine |
| ISSN: | 1532-8171 0735-6757 |
| Popis: | Introduction Monoclonal antibodies received an Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration for the outpatient treatment of mild to moderate coronavirus disease 2019 (COVID-19). REGN-COV2, casirivimab and imdevimab, has been shown to decrease the viral load and healthcare visits of those with mild to moderate COVID-19 who are treated in the outpatient setting. Objective To determine 7- and 14-day emergency department (ED) and hospitalization rates of adult patients given REGN-COV2 for the outpatient treatment of COVID-19 at a community hospital. Methods A convenience sample of consecutive adult patients given REGN-COV2 from January 18, 2021 through March 31, 2021 for the outpatient treatment of mild to moderate COVID-19. Abstracted data included patient demographics, allergic reactions, ED presentations and hospitalizations at 7 and 14 days, and in-hospital mortality. Results A total of 68 patients with a medain age of 69 years (IQR 57–75.5) and 58.3% being female were given REGEN-COV2 during the study period. No allergic reactions were noted during infusion. Of those infused, 18% (12/68) were infused in the ED and had a median length of stay of 477 min. Following infusion, 10% (7/68) of patients re-presented to the ED and 2% (1/68) were hospitalized for COVID-19 at 14 days. In those aged 65 years or greater, 12% (5/42) of patients re-presented to the ED following infusion. Of those who re-presented to the emergency department, the median age was 72.5 years and the median time from infusion to re-presentation was 2.0 days. No patients suffered in-hospital mortality during the study period. Conclusion There was a significant length of stay associated with REGN-COV2 infusion in the emergency department. Following REGN-COV2 infusion, few patients under the age of 65 re-presented to the emergency department at seven and 14 days. However, a large number of patients aged over 65 years re-presented to the ED following infusion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect